alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 726–750 of 851 studies with an author at University College London (GB) (page 30 of 35) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

A population-based study of head injury, cognitive function and pathological markers

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Annals of clinical and translational neurology 2021-03-11

Having a LOC HI aged 50's and younger was linked with lower later-life cognitive function at age ~70 than expected. 2 key findings →

Participants: 502 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma tau biomarkers are distinctly associated with tau tangles and decreased with Lewy body pathology

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-08-01

Understanding how plasma tau biomarkers are influenced by co-pathologies and comorbidities is crucial for their accurate implementation. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The late stage of Parkinson's -results of a large multinational study on motor and non-motor complications

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Parkinsonism & related disorders 2020-05-21

These data suggest that current treatment of late stage parkinsonism in the community remains insufficiently effective to alleviate disabling symptoms in many patients. 3 key findings →

Participants: 692 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Scientific reports 2017-05-30

This study assesses whether C-terminal fragments (CTF) of the amyloid precursor protein (APP) are present in cerebrospinal fluid (CSF) and their potential as biomarkers for Alzheimer's disease (AD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Current opinion in neurobiology 2015-10-24

Neuroinflammation is a pathological hallmark of Alzheimer's disease (AD), and microglia, the brain's resident phagocyte, are pivotal for the immune response observed in AD. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-06-01

Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Can we learn lessons from the FDA's approval of aducanumab?

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Nature reviews. Neurology 2021-09-17

On 7 June 2021, aducanumab was granted accelerated approval for the treatment of Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering effects considered reasonably likely to confer clinical benefit. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid

✓ Peer-reviewed alzhub usefulness score 46 out of 100. EMBO Molecular Medicine 2025-12-01

CSF Aβ42/Aβ40 contributed most to identify Aβ-positivity, while continuous Aβ-PET load within the positive range was best predicted by plasma P-tau217. 1 key finding →

Participants: 1,053 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-Hazard Early Warning Systems in the Sendai Framework for Disaster Risk Reduction: Achievements, Gaps, and Future Directions

✓ Peer-reviewed alzhub usefulness score 46 out of 100. International Journal of Disaster Risk Science 2025-02-01

Bringing together global efforts to enhance the implementation of warnings in managing vulnerabilities, hazards, risks, and disasters is essential to saving lives and for long-term vulnerability reduction. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Loneliness trajectories and dementia risk: Insights from the HUNT cohort study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-07-01

In the fully adjusted model, the odds ratio (OR) for persistent loneliness was 1.47 (95% confidence interval [CI] 1.10, 1.95). 5 key findings →

Participants: 9,389 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation

✓ Peer-reviewed alzhub usefulness score 46 out of 100. npj Parkinson s Disease 2025-08-26

Alpha-synuclein (aSyn) post-translational modifications (PTM), especially phosphorylation at serine 129 and C-terminal truncations, are highly enriched in Lewy bodies (LB), Lewy neurites, and other pathological aggregates in Parkinson's disease and synucleinopathies. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Polygenic risk for white matter hyperintensities is associated with early cerebrovascular events partly through hemodynamic measures in cognitively unimpaired middle-aged and older adults with low cardiovascular risk

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in Neurology 2026-01-05

They are often found in middle-aged individuals and are associated with a greater risk of stroke and vascular dementia. 5 key findings →

Participants: 1,072 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls

✓ Peer-reviewed alzhub usefulness score 45 out of 100. PloS one 2015-05-08

The purpose of the present study was to investigate if cerebrospinal fluid (CSF) biomarkers of neurodegeneration are associated with cognition in bipolar disorder and healthy controls, respectively. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

White matter changes in dementia: role of impaired drainage of interstitial fluid

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain pathology (Zurich, Switzerland) 2015-01-01

White matter abnormalities on magnetic resonance imaging (MRI) are associated with dementia and include white matter hyperintensities (WMH; also termed leukoaraiosis) and visible perivascular spaces (PVS). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Anxiety and depression in family caregivers of people with Alzheimer disease: the LASER-AD study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2005-09-01

Clinicians should be aware of the high rates of anxiety as well as depressive symptoms in family caregivers of people with AD, especially in female caregivers. 1 key finding →

Participants: 153 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed